Company intelligence / Profile preview

Magicell

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

Magicell-NK has been approved for use in Taiwan in several hospitals for cancer therapy; currently in Phase 1/2 trials for multiple solid tumor indications including post-surgery pancreatic duct adenocarcinoma, cholangiocarcinoma, and colon cancer.

Therapeutic areas: Oncology
Modalities: Cell therapyNK cell therapy
Industry: Biotech

Partnerships

NKure Therapeutics (India) for Magicell-NK licensing and development in IndiaTaipei Municipal Wanfang Hospital (Taiwan) for collaborative clinical projectsGya Biotechnology, Xiu Chuan Hospital (Taiwan) for cell therapy delivery

Beyond the preview

Go deeper on Magicell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magicell.

Explore the full profile